Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22142120 | 1.00 | L3MBTL1 (0.39) | L3MBTL1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL22142115 | 1.00 | L3MBTL1 (0.39) | L3MBTL1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL22142114 | 1.00 | L3MBTL1 (0.39) | L3MBTL1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL22142117 | 1.00 | L3MBTL1 (0.39) | L3MBTL1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL22142128 | 1.00 | L3MBTL1 (0.39) | L3MBTL1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL19121481 | 0.93 | L3MBTL1 (0.38) | L3MBTL1 | |
| SCHEMBL13209410 | 0.93 | L3MBTL1 (0.38) | L3MBTL1 | |
| SCHEMBL12018412 | 0.85 | L3MBTL1 (0.42) | L3MBTL1ALDH1A1 | |
| SCHEMBL12597990 | 0.80 | L3MBTL1 (0.36) | L3MBTL1 | |
| SCHEMBL12059740 | 0.79 | L3MBTL1 (0.45) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11667634-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230137816-A1 | ADMINISTRATION OF CALCIUM CHANNEL TRPC6 INHIBITORS USING BALLOONS, STENTS OR OTHER MEDICAL DEVICES | DEUTSCHES HERZZENTRUM MUENCHEN DES FREISTAATES BAYERN (DE) | 2023-05-04 | — | — | US | disclosed |
| US-20230137816-A1 | ADMINISTRATION OF CALCIUM CHANNEL TRPC6 INHIBITORS USING BALLOONS, STENTS OR OTHER MEDICAL DEVICES | DEUTSCHES HERZZENTRUM MUENCHEN DES FREISTAATES BAYERN (DE) | 2023-05-04 | — | — | US | disclosed |
| WO-2021160625-A1 | ADMINISTRATION OF CALCIUM CHANNEL TRPC6 INHIBITORS USING BALLOONS, STENTS OR OTHER MEDICAL DEVICES | KLINIKUM RECHTS DER ISAR (DE) | 2021-08-19 | — | — | WO | disclosed |
| WO-2021093846-A1 | NOVEL TETRACYCLIC HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL USE THEREOF | 上海拓界生物医药科技有限公司 | 2021-05-20 | — | — | WO | disclosed |
| EP-3277286-B1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2021-04-21 | — | — | EP | disclosed |
| US-20210053973-A1 | IMIDAZO[1,2-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2021-02-25 | — | — | US | disclosed |
| US-10351570-B2 | Compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20100197716-A1 | N-LINKED HETEROCYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137816-A1 | ADMINISTRATION OF CALCIUM CHANNEL TRPC6 INHIBITORS USING BALLOONS, STENTS OR OTHER MEDICAL DEVICES | TRPC6, TRPC1, ORAI1 | L3MBTL1 4372/4885ALDH1A1 4066/4885MAPT 3011/4885 |
| US-11667634-B2 | Inhibitors of RAF kinases | BRAF, RAF1, NRAS | L3MBTL1 2623/4885ALDH1A1 3044/4885MAPT 3066/4885 |
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | L3MBTL1 4115/4885ALDH1A1 3522/4885MAPT 439/4885 |
| US-20100197716-A1 | N-LINKED HETEROCYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | P2RY1, P2RY11, P2RY13 | L3MBTL1 4633/4885ALDH1A1 2613/4885MAPT 1569/4885 |
| US-20210053973-A1 | IMIDAZO[1,2-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | ADORA2A, ADORA3, ADORA1 | L3MBTL1 3488/4885ALDH1A1 969/4885MAPT 1520/4885 |
| US-10351570-B2 | Compounds and uses thereof | RB1, VEGFA, FLT4 | L3MBTL1 4854/4885ALDH1A1 1477/4885MAPT 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.